-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
89bio (NASDAQ:ETNB) Trading Down 5.2% Following Insider Selling
89bio (NASDAQ:ETNB) Trading Down 5.2% Following Insider Selling
89bio, Inc. (NASDAQ:ETNB – Get Rating) fell 5.2% on Friday following insider selling activity. The company traded as low as $11.58 and last traded at $11.58. 34,720 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,181,226 shares. The stock had previously closed at $12.21.
Specifically, CFO Ryan Martins sold 5,947 shares of 89bio stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $12.51, for a total transaction of $74,396.97. Following the completion of the sale, the chief financial officer now directly owns 36,368 shares of the company's stock, valued at approximately $454,963.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Ryan Martins sold 5,947 shares of the business's stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $12.51, for a total transaction of $74,396.97. Following the sale, the chief financial officer now owns 36,368 shares of the company's stock, valued at approximately $454,963.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. bought 1,172,741 shares of 89bio stock in a transaction that occurred on Tuesday, October 18th. The stock was bought at an average cost of $7.65 per share, for a total transaction of $8,971,468.65. Following the purchase, the director now owns 8,955,410 shares in the company, valued at approximately $68,508,886.50. The disclosure for this purchase can be found here. Company insiders own 11.80% of the company's stock.
Get 89bio alerts:Analyst Upgrades and Downgrades
Several equities research analysts have commented on ETNB shares. Royal Bank of Canada dropped their price target on shares of 89bio from $35.00 to $29.00 and set an "outperform" rating on the stock in a research note on Friday, November 11th. Raymond James raised their price objective on shares of 89bio from $14.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Wednesday, September 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $34.00 price objective (up previously from $27.00) on shares of 89bio in a research note on Monday, November 14th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $25.25.
89bio Price Performance
The company's fifty day moving average is $9.69 and its two-hundred day moving average is $6.69. The firm has a market capitalization of $537.04 million, a price-to-earnings ratio of -2.65 and a beta of 0.89. The company has a quick ratio of 5.81, a current ratio of 5.81 and a debt-to-equity ratio of 0.08.Institutional Investors Weigh In On 89bio
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP bought a new position in shares of 89bio in the 3rd quarter valued at about $34,000. Acadian Asset Management LLC acquired a new stake in 89bio in the 1st quarter worth about $34,000. Captrust Financial Advisors acquired a new stake in 89bio in the 3rd quarter worth about $60,000. Rhumbline Advisers acquired a new stake in 89bio in the 1st quarter worth about $42,000. Finally, Mirabella Financial Services LLP acquired a new stake in 89bio in the 1st quarter worth about $43,000. 87.78% of the stock is currently owned by institutional investors and hedge funds.
About 89bio
(Get Rating)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
Further Reading
- Get a free copy of the StockNews.com research report on 89bio (ETNB)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.
89bio, Inc. (NASDAQ:ETNB – Get Rating) fell 5.2% on Friday following insider selling activity. The company traded as low as $11.58 and last traded at $11.58. 34,720 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,181,226 shares. The stock had previously closed at $12.21.
受內幕拋售活動影響,新浪納斯達克(Sequoia Capital:ETNB-GET)股價週五下跌5.2%。該公司股價低至11.58美元,最新報11.58美元。午盤成交量為34,720股,較1,181,226股的平均日成交量下降97%。該股此前收盤價為12.21美元。
Specifically, CFO Ryan Martins sold 5,947 shares of 89bio stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $12.51, for a total transaction of $74,396.97. Following the completion of the sale, the chief financial officer now directly owns 36,368 shares of the company's stock, valued at approximately $454,963.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Ryan Martins sold 5,947 shares of the business's stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $12.51, for a total transaction of $74,396.97. Following the sale, the chief financial officer now owns 36,368 shares of the company's stock, valued at approximately $454,963.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. bought 1,172,741 shares of 89bio stock in a transaction that occurred on Tuesday, October 18th. The stock was bought at an average cost of $7.65 per share, for a total transaction of $8,971,468.65. Following the purchase, the director now owns 8,955,410 shares in the company, valued at approximately $68,508,886.50. The disclosure for this purchase can be found here. Company insiders own 11.80% of the company's stock.
具體而言,首席財務官瑞安·馬丁斯在日期為1月3日(星期二)的交易中出售了5,947股89Bio股票。該股以12.51美元的平均價格出售,總成交金額為74,396.97美元。出售完成後,首席財務官現在直接擁有該公司36,368股股票,價值約為454,963.68美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以通過這個環節。在其他新聞方面,首席財務官瑞安·馬丁斯在1月3日星期二的一次交易中出售了5947股該公司的股票。該股以12.51美元的平均價格出售,總成交金額為74,396.97美元。出售後,首席財務官現在擁有該公司36,368股股票,價值約454,963.68美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。此外,董事Ra Capital Management,L.P.在10月18日(星期二)的一筆交易中購買了89Bio1,172,741股股票。這隻股票的平均價格為每股7.65美元,總交易金額為8,971,468.65美元。收購完成後,董事現在擁有該公司8955,410股,價值約68,508,886.50美元。關於這次購買的披露可以找到這裏。公司內部人士持有該公司11.80%的股份。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several equities research analysts have commented on ETNB shares. Royal Bank of Canada dropped their price target on shares of 89bio from $35.00 to $29.00 and set an "outperform" rating on the stock in a research note on Friday, November 11th. Raymond James raised their price objective on shares of 89bio from $14.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Wednesday, September 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $34.00 price objective (up previously from $27.00) on shares of 89bio in a research note on Monday, November 14th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $25.25.
幾位股票研究分析師對ETNB的股票發表了評論。11月11日,加拿大皇家銀行在一份週五的研究報告中將89Bio的目標價從35.00美元下調至29.00美元,並對該股設定了“跑贏大盤”的評級。雷蒙德·詹姆斯在9月14日星期三的一份研究報告中將89Bio的股票目標價從14.00美元上調至25.00美元,並給出了該股“強勢買入”的評級。最後,康託·菲茨傑拉德在11月14日(星期一)的一份研究報告中重申了對89Bio的增持評級,併發布了每股34.00美元的目標價(此前為27.00美元)。七位研究分析師對該股的評級為買入,一位分析師對該公司發出了強烈的買入評級。根據MarketBeat.com的數據,該股的平均評級為買入,共識目標價為25.25美元。
89bio Price Performance
89Bio性價比
Institutional Investors Weigh In On 89bio
機構投資者參與89Bio
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP bought a new position in shares of 89bio in the 3rd quarter valued at about $34,000. Acadian Asset Management LLC acquired a new stake in 89bio in the 1st quarter worth about $34,000. Captrust Financial Advisors acquired a new stake in 89bio in the 3rd quarter worth about $60,000. Rhumbline Advisers acquired a new stake in 89bio in the 1st quarter worth about $42,000. Finally, Mirabella Financial Services LLP acquired a new stake in 89bio in the 1st quarter worth about $43,000. 87.78% of the stock is currently owned by institutional investors and hedge funds.
對衝基金和其他機構投資者最近改變了他們在該股的頭寸。Quantbot Technologies LP在第三季度購買了89Bio的新頭寸,價值約3.4萬美元。Acadian Asset Management LLC在第一季度收購了89Bio的新股份,價值約3.4萬美元。CapTrust Financial Advisors在第三季度收購了89Bio價值約6萬美元的新股份。Rhumbline Advisers在第一季度收購了89Bio的新股份,價值約4.2萬美元。最後,Mirabella Financial Services LLP在第一季度收購了89Bio價值約43,000美元的新股份。87.78%的股票目前由機構投資者和對衝基金持有。
About 89bio
約89Bio
(Get Rating)
(獲取評級)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
89BioInc.是一家臨牀階段的生物製藥公司,專注於治療肝臟和心臟代謝性疾病的療法的開發和商業化。它的主要候選產品是pegozafermin,一種用於治療非酒精性脂肪性肝炎的成纖維細胞生長因子21的糖基化類似物。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on 89bio (ETNB)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
- 免費獲取股票新聞網站89Bio(ETNB)上的研究報告
- MarketBeat:回顧中的一週01/02-01/06
- 為什麼CrowdStrike的股價舉步維艱?
- 2023年四隻被低估的醫療保健股票
- WWE股票:文斯·麥克馬洪想要重返節目
- NVIDIA正在觸底,但現在還不能買入
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.
接受89Bio日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對89Bio和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧